Antimicrobial resistance in Clostridioides difficile

被引：47
作者：
O'Grady, Keeley [1 ]
Knight, Daniel R. [1 ,2 ]
Riley, Thomas, V [1 ,2 ,3 ,4 ]
机构：
[1] Murdoch Univ, Ctr Biosecur & One Hlth, Harry Butler Inst, Murdoch, WA, Australia
[2] Univ Western Australia, Queen Elizabeth II Med Ctr, Marshall Ctr Infect Dis Res & Training, Sch Biomed Sci, Nedlands, WA 6009, Australia
[3] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA, Australia
[4] Queen Elizabeth II Med Ctr, Dept Microbiol, PathWest Lab Med, Nedlands, WA, Australia
来源：
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2021年 / 40卷 / 12期
基金：
英国医学研究理事会;
关键词：
Clostridioides difficile; Antimicrobial resistance; Genome; Phenotype; Genetics; Epidemiology; FLUOROQUINOLONE RESISTANCE; MOLECULAR CHARACTERIZATION; REDUCED SUSCEPTIBILITY; AUSTRALASIAN SOCIETY; MULTIDRUG-RESISTANCE; INFECTION; FIDAXOMICIN; RIFAXIMIN; GENE; MECHANISMS;
D O I：
10.1007/s10096-021-04311-5
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Antimicrobial resistance (AMR) in Clostridioides difficile remains a significant threat to global healthcare systems, not just for the treatment of C. difficile infection (CDI), but as a reservoir of AMR genes that could be potentially transferred to other pathogens. The mechanisms of resistance for several antimicrobials such as metronidazole and MLSB-class agents are only beginning to be elucidated, and increasingly, there is evidence that previously unconsidered mechanisms such as plasmid-mediated resistance may play an important role in AMR in this bacterium. In this review, the genetics of AMR in C. difficile will be described, along with a discussion of the factors contributing to the difficulty in clearly determining the true burden of AMR in C. difficile and how it affects the treatment of CDI.
引用
收藏
页码：2459 / 2478
页数：20
相关论文
共 128 条
[1]   Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA [J].
Ackermann, G ;
Tang, YJ ;
Kueper, R ;
Heisig, P ;
Rodloff, AC ;
Silva, J ;
Cohen, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2348-2353
[2]   Mutations Associated with Reduced Surotomycin Susceptibility in Clostridium difficile and Enterococcus Species [J].
Adams, Hannah M. ;
Li, Xiang ;
Mascio, Carmela ;
Chesnel, Laurent ;
Palmer, Kelli L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) :4139-4147
[3]   Clostridium difficile: Epidemiology, Pathogenicity, and an Update on the Limitations of and Challenges in Its Diagnosis [J].
Alyousef, Abdullah A. .
JOURNAL OF AOAC INTERNATIONAL, 2018, 101 (04) :1119-1126
[4]  
Ammam F, 2012, CAN J MICROBIOL, V58, P547, DOI [10.1139/W2012-002, 10.1139/w2012-002]
[5]   Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis [J].
Artsimovitch, Irina ;
Seddon, Jaime ;
Sears, Pamela .
CLINICAL INFECTIOUS DISEASES, 2012, 55 :S127-S131
[6]  
Australian Commission on Safety and Quality in Health Care, 2018, CLOSTRIDIUM DIFFICIL
[7]   Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection [J].
Baines, Simon D. ;
Wilcox, Mark H. .
ANTIBIOTICS-BASEL, 2015, 4 (03) :267-298
[8]   Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model [J].
Baines, Simon D. ;
Noel, Alan R. ;
Huscroft, Grace S. ;
Todhunter, Sharie L. ;
O'Connor, Rachael ;
Hobbs, Joanne K. ;
Freeman, Jane ;
Lovering, Andy M. ;
Wilcox, Mark H. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (07) :1537-1546
[9]   Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms [J].
Banawas, Saeed S. .
BIOMED RESEARCH INTERNATIONAL, 2018, 2018
[10]   In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile [J].
Begum, Khurshida ;
Basseres, Eugenie ;
Miranda, Julie ;
Lancaster, Chris ;
Gonzales-Luna, Anne J. ;
Carlson, Travis J. ;
Rashid, Tasnuva ;
Eyre, David W. ;
Wilcox, Mark H. ;
Alam, M. Jahangir ;
Garey, Kevin W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (08)
12345678910